Basic information
- CAS
1172-18-5- Standard SMILES
CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl- InChIKey
PUGVROXLRUQCAF-UHFFFAOYSA-N- Molecular formula
- C21H24Cl2FN3O
- Average molar mass
- 424.3 g/mol
- Monoisotopic mass
- 423.1280459
Overview
Flurazepam monohydrochloride is a benzodiazepine.
Names & identifiers
- Preferred name
- Flurazepam Monohydrochloride
- IUPAC
- 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one;hydrochloride
- English name
- 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-benzo-1,4-diazepin-2-one monohydrochloride
- Molecular formula
- C21H24Cl2FN3O
- Molecular weight
- 424.3391632
Names & synonyms
Flurazepam monohydrochloride36105-20-1Flurazepam HCL7C4JH842IJDTXSID401896862H-1,4-Benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-, monohydrochlorideRefChem:599463Monohydrochloride, FlurazepamDTXCID00112177252-867-1DalmateDalmadorm
Show more names
7-Chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3- dihydro-2H-1,4-benzodiazepin-2-one monohydrochloride7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-benzo-1,4-diazepin-2-one monohydrochloride
DalmaneNatam7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one;hydrochlorideEINECS 252-867-1UNII-7C4JH842IJFluzepamDalmate (TN)Fluorazepam hydrochloride
Database identifiers
- CAS
1172-18-5、36105-20-1- PubChem CID
Properties
Computed structural properties
- Topological polar surface area
- 35.9 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 4
- Rotatable bonds
- 6
- Heavy atoms
- 28
- Formal charge
- 0
- Complexity
- 540
Physicochemical properties
- solubility
- Very soluble in water, freely soluble in alcohol.
- FDA UNII
- 7 C4JH842IJ · 7C4JH842IJ
- Symbol(GHS)
- 8 · GHS08,GHS07
- Signal word
- Warning
- Hazard statements
- 302 · H302-H373
- Precautionary statements
- 264 · P264-P270-P301+P312-P330-P501-P260-P314-P501
- RIDADR
- 3249 · 3249
- HazardClass
- 6.1 · 6.1(b)
- PackingGroup
- III
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P260, P264, P270, P301+P317, P319, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 26 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard information
Other Safety InformationIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-, monohydrochloride: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)
Toxicology
Treatment
General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension and CNS depression may be combated by judicious use of appropriate therapeutic agents. If excitation occurs in patients following Flurazepam overdosage, barbiturates should not be used. Flumazenil, a specific benzodiazepine-receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be useful in situations when an overdose with a benzodiazepine is known or suspected. (L1712)
Health EffectsThey cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.
Exposure RoutesOral. Flurazepam hydrochloride is rapidly (30 minutes) absorbed from the gastrointestinal tract
Chemistry & industry
Pharmacology
Metabolism/Metabolites
Flurazepam is rapidly metabolized and is excreted primarily in the urine. Both hydroxyethyl flurazepam (the major metabolite) and N-desalkyl flurazepam are active. The N-desalkyl metabolite is slowly excreted in the urine as the conjugated form Route of Elimination: Flurazepam is rapidly metabolized and is excreted primarily in the urine. Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam. Half Life: The mean apparent half-life of flurazepam is 2.3 hours. The half life of elimination of N1-des-alkyl- flurazepam ranged from 47 to 100 hours
MeSH Pharmacological Classification
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.
Uses & manufacturing
UsesFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
Applications
UsesBenzodiazepine.
Additional notes
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…